Todd L. Cecil - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Todd L. Cecil


Todd L. Cecil
Vice-President,
Compendial Science,
United States Pharmacopeia

Todd L. Cecil, PhD, is the vice-president of compendial science at USP. He has been with the organization since 1993 and has held the following positions: director of noncomplex actives and general policies and requirements; project manager of new monograph development project; scientist; and chemist III.

Cecil is presently a member of the American Association of Pharmaceutical Scientists (AAPS) and ACS. While at AAPS, he has held the positions of secretary treasurer, vice-chair, chair-elect, chair, and past-chair of the APQ Section of AAPS; chair APQ Workshop Committee; and AAPS APQ lead paper screener. He is the author of seven publications and has made more than 60 national and international presentations.

He holds a BS in chemistry from the University of Iowa and a PhD in analytical chemistry from Virginia Commonwealth University.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here